S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
S&P 500   4,298.86
DOW   33,876.78
QQQ   354.50
MarketBeat Week in Review – 6/4 - 6/9
Laser breakthrough could send stock soaring 2,467% (Ad)
How major US stock indexes fared Friday 6/9/2023
FuelCell Is Back To Realistic Valuation
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
New Mexico reaches $500M settlement with Walgreens in opioid case
With GM and Ford embracing Tesla's EV charging technology, here's what it means for consumers
Sell Every Stock, Except ONE (Ticker Revealed) (Ad)
Nigeria's central bank chief arrested after being suspended by president
Closing prices for crude oil, gold and other commodities
NASDAQ:SAVA

Cassava Sciences (SAVA) Stock Forecast, Price & News

$24.31
-0.17 (-0.69%)
(As of 06/9/2023 ET)
Compare
Today's Range
$23.80
$24.64
50-Day Range
$21.59
$27.88
52-Week Range
$13.84
$51.59
Volume
610,491 shs
Average Volume
645,012 shs
Market Capitalization
$1.01 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$54.33

Cassava Sciences MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
123.5% Upside
$54.33 Price Target
Short Interest
Bearish
25.90% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.82
Upright™ Environmental Score
News Sentiment
1.14mentions of Cassava Sciences in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From $0.84 to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.85 out of 5 stars

Medical Sector

734th out of 987 stocks

Pharmaceutical Preparations Industry

358th out of 482 stocks


SAVA stock logo

About Cassava Sciences (NASDAQ:SAVA) Stock

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier in May 1998 and is headquartered in Austin, TX.

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Stock News Headlines

Cassava Sciences (NASDAQ: SAVA)
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
Why Shares of Cassava Sciences Jumped This Week
Cassava Sciences (NASDAQ:SAVA) Shares Up 6%
Cassava Sciences adds 14% most since September
8-K: CASSAVA SCIENCES INC
Buy Cassava Sciences For Imminent Data Readout
See More Headlines

SAVA Price History

SAVA Company Calendar

Last Earnings
5/01/2023
Today
6/10/2023
Next Earnings (Estimated)
8/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SAVA
Employees
24
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$54.33
High Stock Price Forecast
$124.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+123.5%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-76,250,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.68 per share

Miscellaneous

Free Float
37,992,000
Market Cap
$1.01 billion
Optionable
Not Optionable
Beta
-0.15

Key Executives

  • Remi Barbier
    Chairman, President & Chief Executive Officer
  • Eric J. Schoen
    Chief Financial Officer
  • James W. Kupiec
    Chief Medical Officer
  • Michael Zamloot
    Senior Vice President-Technical Operations
  • George B. Thornton
    Senior Vice President-Technology













SAVA Stock - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" SAVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SAVA, but not buy additional shares or sell existing shares.
View SAVA analyst ratings
or view top-rated stocks.

What is Cassava Sciences' stock price forecast for 2023?

3 Wall Street analysts have issued 1-year price targets for Cassava Sciences' shares. Their SAVA share price forecasts range from $11.00 to $124.00. On average, they expect the company's share price to reach $54.33 in the next year. This suggests a possible upside of 123.5% from the stock's current price.
View analysts price targets for SAVA
or view top-rated stocks among Wall Street analysts.

How have SAVA shares performed in 2023?

Cassava Sciences' stock was trading at $29.54 at the start of the year. Since then, SAVA stock has decreased by 17.7% and is now trading at $24.31.
View the best growth stocks for 2023 here
.

When is Cassava Sciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our SAVA earnings forecast
.

How were Cassava Sciences' earnings last quarter?

Cassava Sciences, Inc. (NASDAQ:SAVA) posted its quarterly earnings results on Monday, May, 1st. The company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.02.

When did Cassava Sciences' stock split?

Shares of Cassava Sciences reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Cassava Sciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).

What is Cassava Sciences' stock symbol?

Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."

Who are Cassava Sciences' major shareholders?

Cassava Sciences' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.28%), State Street Corp (2.54%), Geode Capital Management LLC (1.82%), Gallacher Capital Management LLC (1.41%), Susquehanna International Group LLP (0.00%) and Charles Schwab Investment Management Inc. (0.70%). Insiders that own company stock include Eric Schoen, James William Kupiec, Remi Barbier, Richard Barry and Sanford Robertson.
View institutional ownership trends
.

How do I buy shares of Cassava Sciences?

Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cassava Sciences' stock price today?

One share of SAVA stock can currently be purchased for approximately $24.31.

How much money does Cassava Sciences make?

Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $1.01 billion. The company earns $-76,250,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis.

How can I contact Cassava Sciences?

Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for the company is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at ir@paintrials.com, or via fax at 512-501-0414.

This page (NASDAQ:SAVA) was last updated on 6/10/2023 by MarketBeat.com Staff

My Account -